Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 Oct 2016 Status changed from active, no longer recruiting to completed.
- 02 Oct 2015 Endpoints modified as reported in the protocol amendment reported by ClinicalTrials.gov.